Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron (REGN) Tops Q3 Earnings and Revenue Estimates
Regeneron (REGN) came out with quarterly earnings of $12.46 per share, beating the Zacks Consensus Estimate of $11.75 per share. This compares to earnings of $11.59 per share a year ago.
Regeneron beats results estimates on demand for eczema treatment, eye drug
U.S. drugmaker Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven by strong demand for its eczema treatment Dupixent and blockbuster eye disease drug Eylea.
Regeneron to Report Q3 Earnings: What's in the Offing?
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports third-quarter 2024 results.
Top Stocks To Buy Now? 2 Biotech Stocks To Watch
Biotech stocks to keep an eye on in the stock market right now.
Unlocking Q3 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
Regeneron (REGN) Earnings Expected to Grow: Should You Buy?
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regeneron (REGN) Loses -11.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Regeneron (REGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Regeneron Gains 13.5% Year to date: How to Play the Stock?
REGN maintains momentum as Eylea HD gains traction and Dupixent maintains momentum, even as lead drug Eylea faces challenges.
Should You Buy the Dip on This Top Growth Stock?
The biotech needs to overcome an issue most drugmakers face at some point.
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
Chief District Judge Thomas Kleeh denied Regeneron Pharmaceuticals, Inc.‘s REGN effort to prevent the sale of Amgen Inc‘s AMGN Eylea biosimilar.
Regeneron Pharmaceuticals, Inc. (REGN) Wells Fargo 2024 Healthcare Conference (Transcript)
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Wells Fargo 2024 Healthcare Conference September 5, 2024 12:45 PM ET Company Participants Marion McCourt - EVP, Commercial Ryan Crowe - SVP, IR and Strategic Analysis Conference Call Participants Mohit Bansal - Wells Fargo Mohit Bansal Great. So my name is Mohit Bansal, and thank you for the post lunch session.
Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030
Regeneron is an innovative drugmaker that continues to perform well. Shopify's changed and improved business should lead to stronger returns.
